glibenclamide

glibenclamide
Name	Glibenclamide
Routes of administration	Oral
Metabolism	Hepatic
Excretion	Renal
Class	Sulfonylurea

glibenclamide

Glibenclamide is an oral sulfonylurea antihyperglycemic agent used to lower blood glucose in type 2 diabetes mellitus. It belongs to the second‑generation sulfonylureas and acts by stimulating insulin release from pancreatic beta cells; its clinical role, pharmacology, safety profile, and historical development intersect with regulatory agencies, pharmaceutical companies, and international treatment guidelines.

Medical uses

Glibenclamide is prescribed for adults with Type 2 diabetes mellitus inadequately controlled by diet, exercise, or other agents, and is sometimes used in gestational contexts under specialist guidance. Clinical practice guidance from organizations such as the World Health Organization, American Diabetes Association, National Institute for Health and Care Excellence, International Diabetes Federation, and national formularies contrasts glibenclamide with agents like metformin, insulin, pioglitazone, liraglutide, and dapagliflozin. Trials conducted at centers including Mayo Clinic, Johns Hopkins Hospital, Karolinska Institutet, and Imperial College London compared glycemic control, hypoglycaemia risk, and cardiovascular outcomes versus comparators such as glyburide alternatives and combinations with ACE inhibitor therapy. Hospitals and clinics in regions like India, Brazil, United Kingdom, United States, and South Africa report varied prescribing patterns influenced by cost, access, and guideline updates from agencies including the European Medicines Agency, Food and Drug Administration, and national ministries of health.

Mechanism of action

Glibenclamide binds to the sulfonylurea receptor subunit of ATP‑sensitive potassium (KATP) channels on pancreatic beta cells, analogous to interactions described in ATP-binding cassette transporter studies and work from laboratories at University of Cambridge, Harvard Medical School, and Stanford University. This binding inhibits KATP channel activity, causing membrane depolarization, opening of voltage‑gated calcium channels, and calcium‑dependent insulin exocytosis—mechanistic frameworks also explored in research from Max Planck Society and Cold Spring Harbor Laboratory. The drug’s action is contrasted with incretin‑based mechanisms described for GLP‑1 receptor agonists and dipeptidyl peptidase‑4 inhibitors emphasized by investigators at European Association for the Study of Diabetes meetings.

Pharmacokinetics

Absorption, distribution, metabolism, and excretion data derive from pharmacology groups at institutions like Pfizer, GlaxoSmithKline, and university pharmacology departments in Tokyo, Paris, and Milan. Orally administered glibenclamide exhibits hepatic metabolism largely via cytochrome P450 enzymes; metabolic pathways studied in collaboration with National Institutes of Health scientists highlight interactions with isoenzymes such as CYP2C9 and CYP3A4. Protein binding and plasma half‑life estimations inform dosing strategies compared with agents evaluated at Cleveland Clinic and Baylor College of Medicine. Renal elimination and active metabolites shape considerations in patients managed at Mayo Clinic and dialysis centers affiliated with Johns Hopkins Hospital.

Adverse effects and safety

Hypoglycaemia is the principal adverse effect reported in randomized trials and postmarketing surveillance by organizations such as the World Health Organization and national pharmacovigilance centers. Other events—weight gain, cutaneous reactions, hepatic enzyme alterations—have been documented in registries maintained by European Medicines Agency and specialist groups at Mount Sinai Hospital and Karolinska Universitetssjukhuset. Risk stratification for elderly patients, pregnant people, and those with renal or hepatic impairment is discussed in position statements from American Geriatrics Society, Royal College of Obstetricians and Gynaecologists, and regional diabetes associations. Safety debates have engaged regulatory reviews by the Food and Drug Administration and legal and policy analyses in national parliaments and health ministries.

Interactions

Clinically significant interactions arise with agents metabolized by or affecting CYP enzymes and with drugs altering glycemic control. Interaction studies from research centers at University of California, San Francisco, University of Toronto, and pharmaceutical companies documented effects with warfarin, rifampicin, erythromycin, fluconazole, beta blockers, and salicylates. Co‑administration with other hypoglycemic agents such as insulin or metformin increases hypoglycaemia risk, a concern reflected in treatment algorithms from American Diabetes Association and European Society of Cardiology guidance for comorbid cardiovascular disease.

Chemistry and formulation

Glibenclamide is a sulfonylurea derivative with a benzamide and cyclohexylurea core; its chemistry was developed within mid‑20th century organic synthesis programs at companies including Hoechst AG and research groups at University of Basel and ETH Zurich. Formulations include immediate‑release tablets and combinations with agents like metformin hydrochloride produced by multinational manufacturers such as Sanofi, Novartis, and regional generic producers. Solid‑state chemistry, polymorphism, and stability testing have been subjects of studies at materials science labs in Massachusetts Institute of Technology and École Polytechnique Fédérale de Lausanne.

History and society

The development of sulfonylureas emerged from mid‑20th century drug discovery efforts following sulfonamide chemistry explored at institutions like Bayer and Eli Lilly and Company. Glibenclamide’s clinical adoption intersected with public health programs in United Kingdom and India, debates at World Health Organization forums, and health technology assessments by bodies such as National Institute for Health and Care Excellence and national reimbursement agencies. Societal issues include access and affordability discussions in World Trade Organization negotiations, litigation and regulatory review in the United States and European Union, and inclusion on essential medicines lists curated by the World Health Organization.

Category:Sulfonylureas